CD19 and myeloid sarcoma: Limited clinical trials (Phase I) have shown that the use of anti-BCMA CAR-T cells for therapy of recurrent antibody-associated inflammatory diseases of the nervous system (NCT04561557) resulted in remission in 11 of 12 patients at 5.5 months [135]; the use of anti-CD19 CAR-T cells in progressive MS (NCT06138132) led to a reduction in intrathecal IgG in one patient and stabilization of the patient’s condition on the EDSS in another; for anti-CD19 CAR-T cells (KYV-101) (NCT06451159), a safety assessment was conducted in refractory MS.